Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

Summary

The objective of the study is the evaluation of efficacy and safety of obinutuzumab preemptive treatment at the time of the molecular relapse after first line immunochemotherapy with autologous stem cell transplantation in mantle cell lymphoma patients.

Timeline

Start

2018-05-14

Primary completion

2020-01-31

Completion

2020-01-31

Outcome

Outcome not reported

Stopped (Enrollment): “Very slow recruitment due to lack of relapse in the observed group of patients”

Drugs

Indications